Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

o2h Ventures. (2/15/20). "Press Release: o2h Ventures Makes an Investment in Turbine". Cambridge.

Organisations Organisation o2h Ventures Therapeutics and AI Fund
  Group o2h (Group)
  Organisation 2 Turbine Kft.
  Group Turbine (Group)
Products Product Simulated Cell technology
  Product 2 venture capital
Index term Index term Turbine–o2h: investment, 201911 first institutional financing round totalling €3m incl new + co-investor o2h Ventures
Persons Person Shah, Sunil (o2h Discovery Ltd 201806 CEO)
  Person 2 Nagy, Szabolcs (Turbine 201911 CEO + Co-Founder)
     


The o2h Therapeutics and AI Fund (“The Fund”), an early stage S/EIS fund investing in biotechnology therapeutics and related AI opportunities, is pleased to announce an investment in Turbine, a simulation-based drug discovery company.

Based on a decade of research, Turbine’s biologists, bioinformaticians, data scientists, and AI engineers built the Simulated Cell. This platform is comprised of a dynamic computational model of the human cell and the underlying simulation technology to find the smartest route to novel targets, biomarkers, and combination therapies.

Turbine has built a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutic targets or indications, untangling the complexity of cancer.

From the discussion that o2h Ventures has had with large pharma, there is demand for well validated drug targets. With high quality data, AI with its large computing power can be used effectively to understand these complex drug pathways.

Sunil Shah, CEO, o2h Ventures who manages The fund alongside Prashant Shah, said: “We are very excited to be able to invest in Turbine, not only have they developed a great technology platform which big pharma will be attracted to, the entrepreneurs and co-investors are some of the best in the world..”

Szabolcs Nagy, CEO and Co-Founder of Turbine, said, “Even before o2h Ventures joined the syndicate they have been very supportive referring potential advisors, introductions to VC’s and providing advice on developing the business model. They make themselves available to us whenever as required. We welcome them to the team.”


Editor’s Note:

About o2h Ventures:

o2h Ventures Limited has launched the o2h Therapeutics and AI fund which is the first S/EIS fund in the UK solely focused on early stage biotech therapeutics and related AI opportunities. The geographic scope shall be UK wide including Oxford and London but will target the growing Cambridge biotech cluster. The Fund is structured to be S/EIS compliant providing tax breaks for UK taxpayers.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h operate from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit- www.o2hventures.com

Contact:

Ajit Singh
Marketing Manager
ajit@o2h.com


About Turbine:

Turbine was founded on the premise that a predictive computational model of biology will revolutionize drug development.

Designing life-saving therapies today requires a vast investment of money, brainpower, and time. Still, failure results 99 times out of 100. The reason for this is simple – mankind doesn’t understand how human biology works. Turbine was founded on the premise that a predictive, computational model of biology would revolutionize drug discovery much like computer aided design revolutionize engineering.

Our growing team of AI experts, biologists, and data scientists have spent the past decade building this model. Through millions of simulated experiments, Turbine finds the shortest, safest route to new patient therapies, enabling researchers to focus their resources on fighting disease in the most effective way possible.

For more information, please see – www.turbine.ai

Contact:

Szabolcs Nagy
Chief Executive Officer & Co-Founder
szabolcs.nagy@turbine.ai

Daniella Rédei
Head of Marketing
daniella.redei@turbine.ai

   
Record changed: 2020-02-21

Advertisement

Picture [iito] – Putting Information into Context 650x65px

More documents for o2h (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top